CoChat
Sign Up
Cited by 220

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Spertus, John A, Fine, Jennifer T, Elliott, Perry, Ho, Carolyn Y, Olivotto, Iacopo, Saberi, Sara, Li, Wanying, Dolan, Chantal, Reaney, Matthew, Sehnert, Amy J, Jacoby, Daniel·2021·The Lancet
DOI 10.1016/s0140-6736(21)00763-7
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)00763-7

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mavacamten was associated with a significant reduction in left ventricular outflow tract gradient and improvement in quality of life as measured by the Kansas City Cardiomyopathy Questionnaire compared with placebo.

    “Mavacamten was associated with a significant reduction in LVOT gradient and improvement in quality of life as measured by the Kansas City Cardiomyopathy Questionnaire, compared with placebo.47”

    From Current management of hypertrophic cardiomyopathy (2025) · cites this paper as [47]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 30

  1. Maron, 2018, Clinical Course and management of hypertrophic cardiomyopathy, N Engl J Med, 379, 655, 10.1056/NEJMra1710575 · DOI · Paper page
  2. Zaiser, 2020, Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life, J Patient Rep Outcomes, 4, 102, 10.1186/s41687-020-00269-8 · DOI
  3. Elliott, 2014, 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, 35, 2733, 10.1093/eurheartj/ehu284 · DOI · Paper page
  4. Ommen, 2020, 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines, Circulation, 142, e533
  5. Rastegar, 2017, Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience, Ann Cardiothorac Surg, 6, 353, 10.21037/acs.2017.07.07 · DOI
  6. Khalil, 2017, Hypertrophic obstructive cardiomyopathy-the Leipzig experience, Ann Cardiothorac Surg, 6, 337, 10.21037/acs.2017.07.09 · DOI
  7. Fortunato de Cano, 2016, Long-term clinical follow-up of patients undergoing percutaneous alcohol septal reduction for symptomatic obstructive hypertrophic cardiomyopathy, Catheter Cardiovasc Interv, 88, 953
  8. Green, 2016, A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice, Science, 351, 617, 10.1126/science.aad3456 · DOI
  9. Papadakis, 2020, Mavacamten: treatment aspirations in hypertrophic cardiomyopathy, Lancet, 396, 736, 10.1016/S0140-6736(20)31793-1 · DOI
  10. Ho, 2020, Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy, Circ Heart Fail, 13, 10.1161/CIRCHEARTFAILURE.120.006853 · DOI
  11. Olivotto, 2020, Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 396, 759, 10.1016/S0140-6736(20)31792-X · DOI · Paper page
  12. Green, 2000, Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure, J Am Coll Cardiol, 35, 1245, 10.1016/S0735-1097(00)00531-3 · DOI · Paper page
  13. Huff, 2013, Correlations between physician-perceived functional status, patient-perceived health status, and cardiopulmonary exercise results in hypertrophic cardiomyopathy, Qual Life Res, 22, 647, 10.1007/s11136-012-0182-y · DOI
  14. Heidenreich, 2006, Health status identifies heart failure outpatients at risk for hospitalization or death, J Am Coll Cardiol, 47, 752, 10.1016/j.jacc.2005.11.021 · DOI
  15. Soto, 2004, Prognostic value of health status in patients with heart failure after acute myocardial infarction, Circulation, 110, 546, 10.1161/01.CIR.0000136991.85540.A9 · DOI
  16. Chan, 2009, Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS), Circulation, 119, 398, 10.1161/CIRCULATIONAHA.108.820472 · DOI
  17. Spertus, 2005, Monitoring clinical changes in patients with heart failure: a comparison of methods, Am Heart J, 150, 707, 10.1016/j.ahj.2004.12.010 · DOI
  18. Dreyer, 2016, Quantifying clinical change: discrepancies between patients' and providers' perspectives, Qual Life Res, 25, 2213, 10.1007/s11136-016-1267-9 · DOI
  19. Spertus, 2020, Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review, J Am Coll Cardiol, 76, 2379, 10.1016/j.jacc.2020.09.542 · DOI · Paper page
  20. Kosiborod, 2007, Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments, Circulation, 115, 1975, 10.1161/CIRCULATIONAHA.106.670901 · DOI
  21. Pokharel, 2017, Association of serial Kansas City Cardiomyopathy Questionnaire assessments with death and hospitalization in patients with heart failure with preserved and reduced ejection fraction: a secondary analysis of 2 randomized clinical trials, JAMA Cardiol, 2, 1315, 10.1001/jamacardio.2017.3983 · DOI
  22. Ho, 2021, Guidelines on the verge of a more evidence-based era for hypertrophic cardiomyopathy, Circulation, 143, 295, 10.1161/CIRCULATIONAHA.120.050608 · DOI
  23. Heidenreich, 2020, 2020 ACC/AHA clinical performance and quality measures for adults with heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures, J Am Coll Cardiol, 76, 2527, 10.1016/j.jacc.2020.07.023 · DOI
  24. Flynn, 2012, Relationships between changes in patient-reported health status and functional capacity in outpatients with heart failure, Am Heart J, 163, 88, 10.1016/j.ahj.2011.09.027 · DOI
  25. Arnold, 2020, Health status changes and outcomes in patients with heart failure and mitral regurgitation: COAPT trial, J Am Coll Cardiol, 75, 2099, 10.1016/j.jacc.2020.03.002 · DOI
  26. Solomon, 2019, Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction, N Engl J Med, 381, 1609, 10.1056/NEJMoa1908655 · DOI · Paper page
  27. Teerlink, 2021, Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure, N Engl J Med, 384, 105, 10.1056/NEJMoa2025797 · DOI · Paper page
  28. Maurer, 2018, Tafamidis Treatment for patients with transthyretin amyloid cardiomyopathy, N Engl J Med, 379, 1007, 10.1056/NEJMoa1805689 · DOI · Paper page
  29. Greene, 2018, Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry, J Am Coll Cardiol, 72, 351, 10.1016/j.jacc.2018.04.070 · DOI
  30. Haynes, 2002, Helping patients follow prescribed treatment: clinical applications, JAMA, 288, 2880, 10.1001/jama.288.22.2880 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Spertus, J. A., Fine, J. T., Elliott, P., Ho, C. Y., Olivotto, I., Saberi, S., Li, W., Dolan, C., Reaney, M., Sehnert, A. J., & Jacoby, D.
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-06
Volume
397
Issue
10293
Pages
2467-2475
ISSN
0140-6736
DOI
10.1016/s0140-6736(21)00763-7
Cited by
220
References
5
Language
en
Licence
Funders
  • MyoKardia
  • Shire
  • Sanofi Genzyme
  • Bayer Fund

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review